Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion

References

• Bodor N, Harget AJ, Phillips EW. (1983). Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach. J Med Chem 26:318–328.
   PubMed Web of Science ®Google Scholar
• Civiale C, Bucaria F, Piazza S, Peri O, Miano F, Enea V. (2004). Ocular permeability screening of dexamethasone esters through combined cellular and tissue systems. J Ocul Pharmacol Ther 20:75–84.
   Google Scholar
• Fujino A, Ohta S, Shinozawa N, Mukouyama H, Yanagida Y, Hayashi  Y, Uchide M. (1985a). Studies on the metabolic fate of difluprednate (DFBA) (1): absorption, distribution and excretion after subcutaneous administration to rats and rabbits. Oyo Yakuri/Pharmacometrics 29:687–699.
   Google Scholar
• Fujino A, Ohta S, Shinozawa N, Mukouyama H, Yanagida Y, Ichuhara N, Hayashi Y, Uchide M. (1985b). Studies on the metabolic fate of difluprednate (DFBA) (2): absorption, distribution and excretion after dermal application to rats and rabbits. Oyo Yakuri/Pharmacometrics 29:701–712.
   Google Scholar
• Fujino A, Ohta S, Shibata K, Ichihara N, Gotoh A, Shimazu M, Uchide M, Ogawa S, Hayashi Y. (1985c). Studies on the metabolic fate of difluprednate (DFBA) (3): metabolism in rats and rabbits after subcutaneous administration. Oyo Yakuri/Pharmacometrics 29:713–723.
   Google Scholar
• Gupta V, Wagner BJ. (2009). Search for a functional glucocorticoid receptor in the mammalian lens. Exp Eye Res 88:248–256.
   Google Scholar
• Jamal KN, Callanan DG. (2009). The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol 3:381–390.
   PubMedGoogle Scholar
• Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS;, Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. (2009). Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg 35:26–34.
   PubMed Web of Science ®Google Scholar
• Lee VH, Chang SC, Oshiro CM, Smith RE. (1985). Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. Curr Eye Res 4:1117–1125.
   PubMed Web of Science ®Google Scholar
• Nakano S, Yamamoto T, Kirii E, Abe S, Yamashita H. (2010). Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 248:805–810.
   PubMed Web of Science ®Google Scholar
• Navarro J, Girard J, Lacour C, Unkovic J, Lafille C. (1978). Pharmacological study of a new anti-inflammatory steroid, difluprednate (CM 9155). Arzneimittelforschung 28:2302–2311.
   Google Scholar
• Polansky JR, Winereb RN. (1984). Chapter 10a: Anti-inflammatory agents – Steroid as anti-inflammatory agents. In: Martin LS, ed. Pharmacology of the eye. Berlin, Heidelberg, New York, Tokyo: Springer-Verlag, p 459–551.
   Google Scholar
• Sakaki H, Kida T, Tajika T, Nemoto S. (2006). Pharmacological property of difluprednate, a novel strong steroid in ophthalmic use. 6th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT). Poster session 1, Berlin, Germany, March 30 to April 2.
   Google Scholar
• Shindo T, Tsukamoto Y, Yasuda Y, Marunaka T. (1984a). Studies on the metabolic fate of dexamethasone 17, 21-dipropionate (THS-101)(4) Difference of metabolic fate in various species of animals. Oyo Yakuri/Pharmacometrics 27:1073–1083.
   Google Scholar
• Shindo T, Tsukamoto Y, Yasuda Y, Marunaka T, Umeno Y, Minami  Y, Tanaka M. (1984b). Studies on the metabolic fate of Dexamethasone 17, 21-dipropionate (THS-101)(3) Metabolic products and pathway after intravenous injection or topical application in rats. Oyo Yakuri/Pharmacometrics 27:1057–1072.
   Google Scholar
• Tamada Y, Sase Y, Ichinohasama J, Obara Y. (1978). Steroid cataract produced by long term local administration of steroid. Biochemical study on systemic influence on genesis of steroid cataract. Folia Ophthalmol Jpn 29:568–576.
   Google Scholar
• Takahashi K, Arai Y, Kadowaki S. (1985a). Anti-inflammatory activity of difluprednate, a topical anti-inflammatory steroid (1), Effect of local and subcutaneous administration. Oyo Yakuri/Pharmacometrics 29:343–353.
   Google Scholar
• Takahashi K, Kadowaki S, Arai Y, Sugasawa K. (1985b). Anti-inflammatory activity of difluprednate, a topical anti-inflammatory steroid (2), Effect of topical application of difluprednate ointment (DFBA). Oyo Yakuri/Pharmacometrics 29:355–362.
   Google Scholar
• Tripathi RC, Tripathi BJ, Haggerty C. (2003). Drug-induced glaucomas: mechanism and management. Drug Saf 26:749–767.
   PubMed Web of Science ®Google Scholar
• Tsuji A, Tamai I, Sasaki K. (1987). Hydrolysis of prednisolone succinate by esterase in rabbit ocular tissue. Ophthalmic Res 19:322–329.
   PubMed Web of Science ®Google Scholar
• Wojnar RJ, Varma RK, Free CA, Millonig RC, Karanewsky D, Lutsky BN. (1986). Androstene-17-thioketals. 1st communication: glucocorticoid receptor binding, antiproliferative and antiinflammatory activities of some novel 20-thiasteroids (androstene-17-thioketals). Arzneimittelforschung 36:1782–1787.
   Google Scholar
• Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada  K, Ohtori A. (2005). Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 301:121–128.
   PubMed Web of Science ®Google Scholar
• Yamauchi H, Kito H, Uda K. (1975). Studies on intraocular penetration and metabolism of fluorometholone in rabbits: a comparison between dexamethasone and prednisolone acetate. Jap J Ophthalmol 19:339–345.
   Google Scholar
• Yasueda S, Kimura M, Ohtori A, Kakehi K. (2003). Analysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semi-micro HPLC and column switching method. J Pharm Biomed Anal 30:1735–1742.
   PubMed Web of Science ®Google Scholar